Diagnosis of histologically confirmed complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial cancer.
* Patients with a previous diagnosis of AEH or grade 1 endometrial cancer who are already being followed with conservative management with oral or LNG-IUD progestin therapy are eligible.
* For patients with a previous diagnosis of AEH or grade 1 endometrial cancer who have been placed on progestin prior to study entry, the duration of IUD or oral progestin use prior to trial entry should be documented.
Premenopausal woman with a uterus.
ECOG performance status of 0-2.
At least 18 years of age and no more than 45 years of age.
Undergoing uterine-sparing management (e.g. due to interest in fertility preservation, interest in uterine preservation, provider recommendation, or other reason).
BMI ≥ 30 kg/m\^2.
Prior or current receipt of progestin is allowed as above. Willingness to undergo placement of LNG-IUD at the time of study entry.
Ability to understand and willingness to sign an IRB approved written informed consent document.
You may not be if
Current, active treatment for any malignant neoplasm with chemotherapy or radiation.
Pregnant and/or breastfeeding. Participants must have a negative urine or serum pregnancy test during screening window and within 7 days prior to LNG-IUD insertion. If LNG-IUD is in place, lack of pregnancy is assumed.
Active pelvic infection at the time of IUD placement or other contraindication to the use of an IUD in the opinion of the treating physician.
